Pipeline to success for blood clotting research

Prof Mark Sleeman (left) & A/Prof Justin
Hamilton (right)

Australian Centre for Blood Diseases (ACBD) researchers are pushing their discovery of a promising anti-thrombotic agent towards clinical trial as part of a Monash University collaboration with a US biotechnology company. Here’s how the deal was brokered.

by Anne Crawford

In 2014 the ACBD’s Associate Professor Justin Hamilton approached Professor Mark Sleeman at the Monash Biomedicine Discovery Institute (BDI) with a proposal. Professor Sleeman, amongst other roles at Monash Clayton, is the Director of the Monash Antibody Technologies Facility (MATF).

Pipeline to success for anti-blood clotting agent

L-R: Prof Mark Sleeman & A/Prof Justin Hamilton

Pipeline to success: how a Monash-brokered collaboration with a US pharmaceutical company is pushing a Monash discovery to clinical trial.

by Anne Crawford

In 2014, Associate Professor Justin Hamilton approached Professor Mark Sleeman, Director of the Monash Antibody Technologies Facility (MATF), with a proposal. Associate Professor Hamilton, who heads a laboratory in Monash’s Australian Centre for Blood Diseases (ACBD), wanted to use a technology platform the facility had licensed to further his work into a promising anti-thrombotic agent and to jointly apply for seed funding to do this.